117 results on '"Roberts LN"'
Search Results
2. Can edoxaban be used at extremes of bodyweight and in patients with a creatinine clearance ≥95 ml/min? - A population pharmacokinetic analysis.
- Author
-
Clapham RE, Speed V, Byrne R, Roberts LN, Czuprynska J, Gee E, Duffy S, Patel R, Patel RK, Arya R, and Patel JP
- Subjects
- Humans, Female, Male, Aged, Middle Aged, Aged, 80 and over, Adult, Pyridines pharmacokinetics, Pyridines therapeutic use, Thiazoles pharmacokinetics, Thiazoles therapeutic use, Thiazoles blood, Body Weight, Factor Xa Inhibitors pharmacokinetics, Factor Xa Inhibitors therapeutic use, Creatinine blood
- Abstract
Background: Clinical evidence surrounding edoxaban use in patients weighing <50 kg and >120 kg is lacking. The International Society of Thrombosis and Haemostasis Scientific and Standardisation Committee suggests avoiding edoxaban in patients >120 kg. Additionally, concerns exist regarding decreased efficacy in patients prescribed edoxaban for atrial fibrillation with a creatinine clearance (CrCl) >95 ml/min, a finding of the ENGAGE AF-TIMI 48 trial when edoxaban was compared to warfarin., Objective: To derive a population pharmacokinetic (PopPK) model using clinical practice data, to understand the impact of bodyweight and renal function on edoxaban pharmacokinetics., Method: Edoxaban plasma concentrations and patient characteristics were collated from King's College Hospital anticoagulation clinics between 11/2016 and 08/2022. A PopPK model was developed using non-linear mixed effects modelling and used to simulate edoxaban concentrations at the extremes of bodyweight and with varying renal function., Results: Data from 409 patients (46 < 50 kg, 34 > 120 kg and 123 with a CrCl > 95 ml/min) provided 455 edoxaban plasma concentrations. A one-compartment model with between-subject variability on clearance with a proportional error model best described the data. The most significant covariates impacting on edoxaban exposure were CrCl and bodyweight. Our work suggests that edoxaban exposure in patients weighing up to 140 kg is comparable to those weighing 75 kg. Edoxaban exposure is reduced in patients weighing <50 kg due to the recommended dose reductions. There is also a reduction in AUCss when CrCl > 95 ml/min compared to CrCl 80 ml/min., Conclusions: Our population PK model for edoxaban suggests that renal function is a key driver for overall edoxaban exposure. Further clinical outcome data is required to understand clinical effectiveness and adverse outcomes., Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Rachel E. Clapham reports financial support was provided by National Institute for Health Research. Victoria Speed reports a relationship with Bayer that includes: speaking and lecture fees. Lara N. Roberts reports a relationship with Chugai that includes: speaking and lecture fees. Lara N. Roberts reports a relationship with Hemab that includes: consulting or advisory. Emma Gee reports a relationship with Sanofi that includes: speaking and lecture fees. Emma Gee reports a relationship with Cardinal Health that includes: speaking and lecture fees. Emma Gee reports a relationship with Bayer that includes: speaking and lecture fees. Sinead Duffy reports a relationship with Cardinal Health that includes: speaking and lecture fees. Roopen Arya reports a relationship with Sanofi that includes: speaking and lecture fees. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
3. Anticoagulation for stroke prevention in atrial fibrillation and treatment of venous thromboembolism and portal vein thrombosis in cirrhosis: guidance from the SSC of the ISTH.
- Author
-
Carlin S, Cuker A, Gatt A, Gendron N, Hernández-Gea V, Meijer K, Siegal DM, Stanworth S, Lisman T, and Roberts LN
- Subjects
- Humans, Risk Factors, Treatment Outcome, Hemorrhage chemically induced, Blood Coagulation drug effects, Risk Assessment, Heparin, Low-Molecular-Weight therapeutic use, Heparin, Low-Molecular-Weight administration & dosage, Atrial Fibrillation drug therapy, Atrial Fibrillation complications, Atrial Fibrillation diagnosis, Liver Cirrhosis complications, Liver Cirrhosis drug therapy, Portal Vein, Anticoagulants therapeutic use, Anticoagulants administration & dosage, Anticoagulants adverse effects, Venous Thromboembolism prevention & control, Venous Thromboembolism drug therapy, Venous Thromboembolism etiology, Venous Thromboembolism diagnosis, Venous Thrombosis prevention & control, Venous Thrombosis drug therapy, Venous Thrombosis etiology, Venous Thrombosis diagnosis, Stroke prevention & control, Stroke etiology
- Abstract
While advanced liver disease was previously considered to be an acquired bleeding disorder, there is increasing recognition of an associated prothrombotic state with patients being at higher risk of atrial fibrillation (AF) and stroke and venous thromboembolism (VTE) including portal vein thrombosis (PVT). We review the available literature on epidemiology, pathophysiology, and risk factors and provide guidance on anticoagulant management of these conditions in adults with cirrhosis. In patients with Child-Pugh A or B cirrhosis and AF, we recommend anticoagulation with standard-dose direct oral anticoagulants (DOACs) in accordance with cardiology guideline recommendations for patients without liver disease. In those with Child-Pugh C cirrhosis, there is inadequate evidence with respect to the benefit and risk of anticoagulation for stroke prevention in AF. In patients with cirrhosis and acute deep vein thrombosis or pulmonary embolism, we recommend anticoagulation and suggest use of either a DOAC or low-molecular-weight heparin (LMWH)/vitamin K antagonist (VKA) in Child-Pugh A or B cirrhosis and LMWH alone (or as a bridge to VKA in patients with a normal baseline international normalized ratio) in Child-Pugh C cirrhosis. We recommend anticoagulation for patients with cirrhosis and symptomatic PVT. We suggest anticoagulation for those with asymptomatic, progressing PVT and recommend continuing extended anticoagulation for liver transplant candidates with PVT., Competing Interests: Declaration of competing interests S.C. has received speaker or advisory board fees from AstraZeneca, BMS/Pfizer, Fresenius Kabi, Leo Pharma, and Servier. A.C. has served as a consultant for MingSight Pharmaceuticals, the New York Blood Center, Sanofi, and Synergy, and has received authorship royalties from UpToDate. A.G. has received travel/conference awards from Octapharma and CSL Behring. N.G. has received consulting fees or travel awards from Bayer, Bristol-Myers Squibb/Pfizer, LEO Pharma, and Diagnostica Stago. V.H.G. has received speaker fees from Cook Medical and Gore Medical. K.M. has received speaker fees from Alexion, Bayer, and CSL Behring; fees for participation in trial steering committees for Bayer and AstraZeneca; consulting fees from uniQure and Therini, and fees for participation in data monitoring and endpoint adjudication committee for Octapharma. D.M.S. has received honoraria paid indirectly to her research institute from AstraZeneca, BMS-Pfizer, Roche, and Servier for educational presentations. D.M.S. is supported by a Tier 2 Canada Research Chair in Anticoagulant Management of Cardiovascular Disease. L.R. has received speaker or advisory fees from Chugai and Hemab. S.S. and T.L. have no competing interests to disclose., (Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
4. Prevention and management of venous thrombosis in patients with cirrhosis.
- Author
-
Roberts LN and Thachil J
- Abstract
Venous thromboembolism (VTE), particularly portal vein thrombosis, is common in patients with cirrhosis. Misconceptions around the increased bleeding risk in this patient group may lead to delayed and/or inadequate anticoagulation. This nutshell review focusses on the approach to management including the role of direct oral anticoagulants in the treatment of VTE in patients with cirrhosis., (© 2024 The Author(s). British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
5. Advances and current research in primary thromboprophylaxis to prevent hospital-associated venous thromboembolism.
- Author
-
Roberts LN, Arya R, and Hunt BJ
- Subjects
- Humans, Anticoagulants therapeutic use, Hospitalization, Female, Pregnancy, Venous Thromboembolism prevention & control, Venous Thromboembolism etiology
- Abstract
Hospital-associated venous thromboembolism (VTE) is defined as any case of VTE occurring during hospital admission and for up to 90 days post discharge. It accounts for over 50% of all cases of VTE internationally; indeed, there are an estimated 10 million cases of hospital-associated VTE annually. Over the last decade, there has been increasing interest in improving VTE risk assessment and thromboprophylaxis. This review summarises all the recent and ongoing major research studies and future challenges in the different areas, including medical, surgical and obstetric patients, as well as special areas such as lower limb immobilisation. We include sections on both pharmacological and mechanical thromboprophylaxis., (© 2024 British Society for Haematology and John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
6. Perinatal outcomes of pregnancies complicated by prenatally resolved fetal growth restriction.
- Author
-
Roberts LN, Perkins H, Craig WY, and Wax JR
- Subjects
- Humans, Pregnancy, Female, Infant, Newborn, Adult, Ultrasonography, Prenatal, Fetal Growth Retardation, Pregnancy Outcome
- Published
- 2024
- Full Text
- View/download PDF
7. Venous Thromboembolism Risk Assessment Models for Acutely Ill Medical Patients-Back to the Drawing Board?
- Author
-
Roberts LN and Arya R
- Subjects
- Humans, Risk Assessment methods, Acute Disease, Male, Risk Factors, Female, Venous Thromboembolism
- Published
- 2024
- Full Text
- View/download PDF
8. Maternity Leave Satisfaction Among Physicians Compared with Nonphysician Professionals.
- Author
-
Hoang Roberts LN, Zwaans BMM, Vollstedt A, Sharrak A, Han E, Fischer M, Sirls L, and Padmanabhan P
- Subjects
- Adult, Female, Humans, Infant, Newborn, Pregnancy, Mothers, Personal Satisfaction, Postpartum Period, United States, Parental Leave, Physicians
- Abstract
Objective: The objective of this study was to compare maternity leave satisfaction between physicians and nonphysicians. Currently, paid maternal leave is not guaranteed in the United States, resulting in palpable dissatisfaction among parents. Previous studies have shown associations between length of paid leave and career satisfaction and maternal happiness. Materials and Methods: A Qualtrics
® electronic survey was distributed to female professionals through email and social media from April 2019 to March 2020. Inclusion criterion was ≥1 child by birth or adoption, or active pregnancy. Continuous and categorical data were analyzed using two-sample t -test and chi-square, respectively. Results: Of 808 respondents, 77% were physicians. Mean age at birth/adoption of first child was higher in physicians versus nonphysicians (32.1 years vs. 29.7 years; p < 0.001). Physicians took shorter maternity leave than nonphysicians (10.9 weeks vs. 12.0 weeks, p = 0.017) with half of that time paid by employers (5.4 weeks vs. 5.9 weeks, p = 0.2). Dissatisfaction was high among physicians (85.1%) and nonphysicians (92.4%) that correlates with maternity leave compensation dissatisfaction (49% vs. 71.3%, p < 0.001). Thirty-four percent of physicians versus 41% of nonphysicians stated that their health was negatively impacted by maternity leave length. Physicians and nonphysicians reported similar incidences of depression, and breastfeeding, delivery, and other postpartum complications. When queried, 38.8% of physicians and 57% of nonphysicians said they would desire >16 weeks of paid maternity leave ( p < 0.001). Conclusions: In conclusion, dissatisfaction among professional women on maternity leave duration and compensation is high in the United States. Given health implications for both mother and child, this should invite further discussion and changes.- Published
- 2024
- Full Text
- View/download PDF
9. How to manage hemostasis in patients with liver disease during interventions.
- Author
-
Roberts LN
- Subjects
- Humans, Hemostasis, Liver Diseases complications, Blood Coagulation Disorders, Thrombocytopenia therapy, Hemostatics
- Abstract
Patients with advanced chronic liver disease (CLD) often need procedures to both treat and prevent complications of portal hypertension such as ascites or gastrointestinal bleeding. Abnormal results for hemostatic tests, such as prolonged prothrombin time, international normalized ratio, and/or thrombocytopenia, are commonly encountered, raising concerns about increased bleeding risk and leading to transfusion to attempt to correct prior to interventions. However hemostatic markers are poor predictors of bleeding risk in CLD, and routine correction, particularly with fresh frozen plasma and routine platelet transfusions, should be avoided. This narrative review discusses the hemostatic management of patients with CLD using 2 case descriptions., (Copyright © 2023 by The American Society of Hematology.)
- Published
- 2023
- Full Text
- View/download PDF
10. Performance of age-adjusted and fixed threshold D-dimer to exclude DVT in those with low pre-test probability - Single centre experience.
- Author
-
Gazes A, Speed V, Czuprynska JR, Vadher B, Arya R, and Roberts LN
- Subjects
- Humans, Fibrin Fibrinogen Degradation Products, Probability, Predictive Value of Tests, Venous Thrombosis diagnosis
- Abstract
Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
- Published
- 2023
- Full Text
- View/download PDF
11. Assessing the validity and responsiveness of a generic preference quality of life measure in the context of posttraumatic stress disorder.
- Author
-
Matthews SR, Elizabeth M, Roberts LN, Kaambwa B, Wade TD, and Nixon RDV
- Subjects
- Humans, Surveys and Questionnaires, Outcome Assessment, Health Care, Data Accuracy, Reproducibility of Results, Psychometrics, Quality of Life psychology, Stress Disorders, Post-Traumatic therapy
- Abstract
Purpose: There is limited research exploring the usefulness of generic preference-based quality of life (GPQoL) measures used to facilitate economic evaluation in the context of posttraumatic stress disorder (PTSD). The aim of the current study was to explore the validity and responsiveness of a common GPQoL measure (Assessment of Quality of Life 8 Dimension [AQoL-8D]) in relation to a PTSD condition-specific outcome measure (Posttraumatic Stress Disorder Checklist for the DSM-5 [PCL-5])., Method: This aim was investigated in a sample of individuals (N = 147) who received trauma-focused cognitive-behavioural therapies for posttraumatic stress disorder. Convergent validity was investigated using spearman's correlations, and the level of agreement was investigated using Bland-Altman plots. Responsiveness was investigated by exploring the standardised response means (SRM) from pre-post-treatment across the two measures, which allow the comparison of the magnitude of change between the measures over time., Results: Correlations between the AQoL-8D (dimensions, utility and summary total scores) and the PCL-5 total score ranged from small to large and agreement between the measures was considered moderate to good. While SRMs were large for the AQoL-8D and PCL-5 total scores, the SRM for the PCL-5 was nearly double that of the AQoL-8D., Conclusion: Our findings demonstrate that the AQoL-8D has good construct validity but present preliminary evidence that economic evaluations using only GPQoL measures may not fully capture the effectiveness of PTSD treatments., (© 2023. Crown.)
- Published
- 2023
- Full Text
- View/download PDF
12. The ISTH SSC subcommittee on Hemostatic Management of Patients with Liver Disease: goals, ambitions, and call for collaboration: reply.
- Author
-
Lisman T, Carlin S, Gatt A, Hernández-Gea V, Luyendyk JP, Roberts LN, and Stanworth SJ
- Subjects
- Humans, Goals, Hemostatics adverse effects, Liver Diseases diagnosis, Liver Diseases drug therapy
- Abstract
Competing Interests: Declaration of competing interests There are no competing interests to disclose.
- Published
- 2023
- Full Text
- View/download PDF
13. Response to "Clinically relevant increases in the international normalized ratio and model of end-stage liver disease score by therapeutic doses of direct oral anticoagulants in patients with cirrhosis".
- Author
-
Patel JP, Thavarajah V, and Roberts LN
- Published
- 2023
- Full Text
- View/download PDF
14. Systematic Review and Meta-Analysis of Stepped Care Psychological Prevention and Treatment Approaches for Posttraumatic Stress Disorder.
- Author
-
Roberts LN and Nixon RDV
- Subjects
- Adult, Child, Adolescent, Humans, Psychotherapy, Quality of Life, Stress Disorders, Post-Traumatic prevention & control, Stress Disorders, Post-Traumatic diagnosis, Cognitive Behavioral Therapy
- Abstract
Stepped care approaches have been developed to increase treatment accessibility for individuals with posttraumatic stress disorder (PTSD). However, despite guidelines recommending stepped care, it is currently unclear how the approach compares to other treatments for PTSD in terms of symptom reduction, cost, and client-rated acceptability. We conducted a systematic review and meta-analysis of randomized controlled and open trials evaluating stepped care prevention (i.e., targeting those with recent trauma exposure at risk of developing PTSD) and treatment approaches for adults and adolescents/children with PTSD. Eight prevention and four treatment studies were included. There was considerable variation in the sample types, stepped approaches, and control conditions. Most studies found no significant differences between stepped care (both prevention and treatment) and control (active and usual care) in terms of PTSD severity, loss of PTSD diagnosis, depression severity, and quality of life at the final follow-up. There was some evidence to suggest that stepped care was more cost-effective, and as acceptable or more acceptable compared to controls. Interpretations were tempered by high statistical heterogeneity, risk of bias, and lack of recommended evidence-based treatments. Stepped care can make PTSD treatment more accessible; however, more high-quality research is needed comparing stepped care to active controls., (Copyright © 2023. Published by Elsevier Ltd.)
- Published
- 2023
- Full Text
- View/download PDF
15. Prevention of hospital-associated venous thromboembolism - Insight from the Getting It Right First Time thrombosis survey in England.
- Author
-
Roberts LN, Hunt BJ, Briggs TW, and Arya R
- Subjects
- Humans, Anticoagulants therapeutic use, Hospitals, England epidemiology, Venous Thromboembolism epidemiology, Venous Thromboembolism etiology, Venous Thromboembolism prevention & control, Thrombosis drug therapy
- Abstract
A national Venous Thromboembolism (VTE) Prevention Programme was introduced in England in 2010, with limited subsequent study of its impact. Whilst the National Outcomes Framework reports VTE deaths related to hospitalisation annually, there are little data regarding VTE prevention practice or non-fatal VTE associated with hospitalisation. We report the first national thrombosis survey undertaken in collaboration with Getting It Right First Time. 98 Trusts (103 sites, 67% of 144 invited) participated in at least one survey, contributing data regarding VTE prevention in 9553 patients. Anti-coagulant thromboprophylaxis was prescribed to 88% (when indicated), with 8.1% of patients missing doses. Written patient information was provided to 31%. Of 4595 episodes of hospital-associated VTE, 13% were considered potentially preventable. The survey highlights the success of the national programme and areas for improvement in delivery of thromboprophylaxis and patient information., (© 2022 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.)
- Published
- 2023
- Full Text
- View/download PDF
16. The ISTH SSC Subcommittee on Hemostatic Management of Patients with Liver Disease: goals, ambitions, and call for collaboration.
- Author
-
Lisman T, Carlin S, Gatt A, Hernandez-Gea V, Luyendyk JP, Roberts LN, and Stanworth SJ
- Subjects
- Humans, Goals, Hemostasis, Hemostatics adverse effects, Liver Diseases diagnosis, Liver Diseases drug therapy
- Published
- 2023
- Full Text
- View/download PDF
17. The " lived " experience of menstruating women commencing anticoagulants.
- Author
-
Sheikh U, Ding A, Nzelu O, Roberts LN, Johns J, Ross J, Arya R, and Patel JP
- Abstract
Background: Although there is increased recognition that many menstruating women commenced on anticoagulants experience heavy menstrual bleeding, little research has been published describing what women go through and actually experience., Objectives: The aim of this study was to understand the " lived " experience of menstruating women commencing anticoagulants., Methods: We undertook a qualitative study using semistructured interviews. Women who had taken part in the parent PERIOD study and expressed an interest in an in-depth interview were recruited. Interviews were conducted online, and transcripts were generated through MS Teams. Data were analyzed using thematic analysis. Ethics committee approval: REC reference: 19/SW/0211., Results: A total of 15 participants were interviewed. The median age of the participants was 36 years (range, 20-49 years). The following 7 primary themes emerged from the interviews: (1) information received when commencing anticoagulation, (2) mood, (3) strategies used to manage heavy bleeding, (4) social/family life, (5) work life, (6) finances, and (7) multiple health issues-with saturation of themes achieved following 9 interviews. Women affected by heavy menstrual bleeding experienced a negative change in their work/social life and mood., Conclusion: Heavy menstrual bleeding experienced by women commencing anticoagulants has a significant impact on their lives. Recognized measures should be employed to support and minimize the problem for menstruating people., (© 2023 The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
18. Re: Diabetes mellitus is associated with a higher relative risk for venous thromboembolism in females than in males.
- Author
-
Roberts LN and Whyte MB
- Subjects
- Male, Humans, Female, Risk Factors, Venous Thromboembolism etiology, Venous Thromboembolism complications, Diabetes Mellitus epidemiology
- Abstract
Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
- Published
- 2023
- Full Text
- View/download PDF
19. How do anticoagulants impact menstrual bleeding and quality of life? - The PERIOD study.
- Author
-
Patel JP, Nzelu O, Roberts LN, Johns J, Ross J, and Arya R
- Abstract
Background: There is increasing recognition that menstruating women prescribed anticoagulants experience heavy menstrual bleeding., Objectives: The aim of this study is to report the extent of bleeding in menstruating women after commencing anticoagulants and the impact it has on their quality of life., Methods: Women aged 18 to 50, initiated on anticoagulant therapy, were approached to take part in the study. In parallel, a control group of women was also recruited. Women were asked to complete the menstrual bleeding questionnaire and a pictorial blood assessment chart (PBAC) during their next 2 menstrual cycles. Differences between the control and anticoagulated group were compared. Significance was considered at < .05. Ethics committee approval: REC reference: 19/SW/0211., Results: Fifty-seven women in the anticoagulation and 109 women in the control group returned their questionnaires. Women in the anticoagulated group reported an increase in the median length of their menstrual cycle from 5 to 6 days after commencing anticoagulation, compared to 5 days for women in the control group ( P < .05). Anticoagulated women reported significantly higher PBAC scores as compared to the control group ( P < .05), with two-thirds of women in the anticoagulation group reporting heavy menstrual bleeding. Women in the anticoagulation group reported worsening quality of life scores following the initiation of anticoagulation, compared with women in the control group ( P < .05)., Conclusion: Heavy menstrual bleeding occurred in two-thirds of women commencing anticoagulants, who completed a PBAC, which had negative impact on their quality of life. Clinicians commencing anticoagulation therapy should be mindful of this, and recognized measures should be taken to help minimize this problem for menstruating individuals., (© 2023 The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
20. A systematic approach to venous thromboembolism prevention: a focus on UK experience.
- Author
-
Clapham RE and Roberts LN
- Abstract
Venous thromboembolism (VTE) remains a leading cause of preventable morbidity and mortality associated with hospitalization. Despite evidence that providing appropriate thromboprophylaxis to those at risk of VTE in hospital, recent data suggest that the delivery of thromboprophylaxis remains suboptimal across the globe, with a lack of standardization in approach to VTE prevention. This review considers the role of VTE risk assessment and interventions to improve the implementation of the VTE prevention pathway and highlights the systematic approach to VTE prevention adopted in England and its impact. Finally, the critical areas for further research and the emerging data presented during the 2022 ISTH annual congress in London, UK, are summarized., (© 2022 The Authors.)
- Published
- 2022
- Full Text
- View/download PDF
21. "Periprocedural management of abnormal coagulation parameters and thrombocytopenia in patients with cirrhosis: Guidance from the SSC of the ISTH": Reply.
- Author
-
Roberts LN, Lisman T, Stanworth S, Hernandez-Gea V, Magnusson M, Tripodi A, and Thachil J
- Subjects
- Humans, Liver Cirrhosis complications, Liver Cirrhosis diagnosis, Liver Cirrhosis therapy, Blood Coagulation, Thrombocytopenia diagnosis, Thrombocytopenia therapy
- Published
- 2022
- Full Text
- View/download PDF
22. Thromboprophylaxis for venous thromboembolism prevention in hospitalized patients with cirrhosis: Guidance from the SSC of the ISTH.
- Author
-
Roberts LN, Hernandez-Gea V, Magnusson M, Stanworth S, Thachil J, Tripodi A, and Lisman T
- Subjects
- Anticoagulants adverse effects, Fondaparinux therapeutic use, Heparin adverse effects, Heparin, Low-Molecular-Weight adverse effects, Humans, Liver Cirrhosis complications, Liver Cirrhosis diagnosis, Thrombosis drug therapy, Venous Thromboembolism diagnosis, Venous Thromboembolism etiology, Venous Thromboembolism prevention & control
- Abstract
Hospital-associated venous thromboembolism (HA-VTE) is a major cause of morbidity and mortality and is internationally recognized as a significant patient safety issue. While cirrhosis was traditionally considered to predispose to bleeding, these patients are also at an increased risk of VTE, with an associated increase in mortality. Hospitalization rates of patients with cirrhosis are increasing, and decisions regarding thromboprophylaxis are complex due to the uncertain balance between thrombosis and bleeding risk. This is further accentuated by derangements of hemostasis in patients with cirrhosis that are often considered contraindications to pharmacological thromboprophylaxis. Due to the strict inclusion and exclusion criteria of seminal studies of VTE risk assessment and thromboprophylaxis, there is limited data to guide decision making in this patient group. This guidance document reviews the incidence and risk factors for HA-VTE in patients with cirrhosis, outlines evidence to inform the use of thromboprophylaxis, and provides pragmatic recommendations on VTE prevention for hospitalized patients with cirrhosis. In brief, in hospitalized patients with cirrhosis: We suggest inclusion of portal vein thrombosis as a distinct clinically important endpoint for future studies. We recommend against the use of thrombocytopenia and/or prolongation of prothrombin time/international normalized ratio as absolute contraindications to anticoagulant thromboprophylaxis. We suggest anticoagulant thromboprophylaxis in line with local protocols and suggest low molecular weight heparin (LMWH) or fondaparinux over unfractionated heparin (UFH). In renal impairment, we suggest LMWH over UFH. For critically ill patients, we suggest case-by-case consideration of thromboprophylaxis. We recommend research to refine VTE risk stratification, and to establish the optimal dosing and duration of thromboprophylaxis., (© 2022 International Society on Thrombosis and Haemostasis.)
- Published
- 2022
- Full Text
- View/download PDF
23. Illustrated State-of-the-Art Capsules of the ISTH 2022 Congress.
- Author
-
Ariëns RA, Hunt BJ, Agbani EO, Ahnström J, Ahrends R, Alikhan R, Assinger A, Bagoly Z, Balduini A, Barbon E, Barrett CD, Batty P, Carneiro JDA, Chan WS, de Maat M, de Wit K, Denis C, Ellis MH, Eslick R, Fu H, Hayward CPM, Ho-Tin-Noé B, Klok FA, Kumar R, Leiderman K, Litvinov RI, Mackman N, McQuilten Z, Neal MD, Parker WAE, Preston RJS, Rayes J, Rezaie AR, Roberts LN, Rocca B, Shapiro S, Siegal DM, Sousa LP, Suzuki-Inoue K, Zafar T, and Zhou J
- Abstract
The ISTH London 2022 Congress is the first held (mostly) face-to-face again since the COVID-19 pandemic took the world by surprise in 2020. For 2 years we met virtually, but this year's in-person format will allow the ever-so-important and quintessential creativity and networking to flow again. What a pleasure and joy to be able to see everyone! Importantly, all conference proceedings are also streamed (and available recorded) online for those unable to travel on this occasion. This ensures no one misses out. The 2022 scientific program highlights new developments in hemophilia and its treatment, acquired and other inherited bleeding disorders, thromboinflammation, platelets and coagulation, clot structure and composition, fibrinolysis, vascular biology, venous thromboembolism, women's health, arterial thrombosis, pediatrics, COVID-related thrombosis, vaccine-induced thrombocytopenia with thrombosis, and omics and diagnostics. These areas are elegantly reviewed in this Illustrated Review article. The Illustrated Review is a highlight of the ISTH Congress. The format lends itself very well to explaining the science, and the collection of beautiful graphical summaries of recent developments in the field are stunning and self-explanatory. This clever and effective way to communicate research is revolutionary and different from traditional formats. We hope you enjoy this article and will be inspired by its content to generate new research ideas., (© 2022 The Authors. Research and Practice in Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis (ISTH).)
- Published
- 2022
- Full Text
- View/download PDF
24. Prevalence of Bleeding and Thrombosis in Critically Ill Patients with Chronic Liver Disease.
- Author
-
Ow TW, Fatourou E, Rabinowich L, van den Boom B, Nair S, Patel VC, Hogan B, McPhail M, Roberts LN, and Bernal W
- Subjects
- Anticoagulants, Critical Illness, Gastrointestinal Hemorrhage epidemiology, Humans, Middle Aged, Prevalence, Retrospective Studies, Risk Factors, Carcinoma, Hepatocellular complications, Carcinoma, Hepatocellular epidemiology, Liver Neoplasms complications, Liver Neoplasms epidemiology, Thrombosis complications, Venous Thromboembolism diagnosis, Venous Thromboembolism epidemiology, Venous Thromboembolism etiology
- Abstract
Introduction: Hemorrhage and venous thromboembolism (VTE) are recognized complications of chronic liver disease (CLD), but their prevalence and risk factors in critically ill patients are uncertain., Patients and Methods: We studied a retrospective cohort of patients with CLD nonelectively admitted to a specialist intensive care unit (ICU) determining the prevalence and timing of major bleeding and VTE (early, present on admission/diagnosed within 48 hours; later, diagnosed >48 hours post-ICU admission). Associations with baseline clinical and laboratory characteristics, multiorgan failure (MOF), blood product administration, and mortality were explored. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using logistic regression., Results: Of 623 patients with median age 52, bleeding (>48 hours after admission) occurred in 87 (14%) patients. Bleeding was associated with greater illness severity and increased mortality. Gastrointestinal bleeding accounted for 72% of events, secondary to portal hypertension in >90%. Procedure-related bleeding was uncommon. VTE occurred in 125 (20%) patients: early VTE in 80 (13%) and involving the portal vein in 85%. Later VTE affected 45 (7.2%) patients. Hepatocellular carcinoma (HCC) and nonalcoholic liver disease were independently associated with early VTE (OR: 2.79, 95% CI: 1.5-5.2 and OR: 2.32, 95% CI: 1.4-3.9, respectively), and HCC, sepsis, and cryoprecipitate use with late VTE (OR: 2.45, 95% CI: 1.11-5.43; OR: 2.26, 95% CI: 1.2-4.3; and OR: 2.60, 95% CI: 1.3-5.1)., Conclusion: VTE was prevalent on admission to critical care and less commonly developed later. Bleeding was associated with MOF and increased mortality. Severe MOF was not associated with an increased rate of VTE which was linked with HCC, and specific etiologies of CLD., Competing Interests: None declared., (Thieme. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
25. Client Versus Clinicians' Standards of Clinically Meaningful Change and the Effects of Treatment Expectations on Therapeutic Outcomes in Individuals With Posttraumatic Stress Disorder.
- Author
-
Matthews SR, Elizabeth M, Roberts LN, and Nixon RDV
- Subjects
- Adult, Humans, Motivation, Self Report, Treatment Outcome, Cognitive Behavioral Therapy methods, Stress Disorders, Post-Traumatic diagnosis, Stress Disorders, Post-Traumatic therapy
- Abstract
There is limited research on the concordance between client perceptions and clinician standards of the degree of symptom change required to achieve meaningful therapeutic improvement. This was investigated in an adult sample (N = 147) who received trauma-focused cognitive-behavioral therapies for posttraumatic stress disorder (PTSD). We examined whether clients' benchmarks of change were related to actual outcomes and the relationship between client expectations and their treatment outcomes. Clients completed measures indexing the level of symptom reduction required (in their view) to reflect a benefit or recovery from treatment and treatment expectations. Actual PTSD severity was indexed pre- and posttreatment via self-report and clinician-administered interview. Results demonstrated that the amount of change clients said they required to experience a benefit or recovery was significantly larger than typical clinical research standards. Nonetheless, the majority of client benchmarks of change (79.7-81.8%) were consistent with clinical research standards of what constitutes benefit or recovery. Client benchmarks were generally positively correlated with their actual outcomes. Clients' belief that treatment would be successful was associated with greater reductions in PTSD symptoms. These findings provide preliminary evidence that the standards used to determine clinically significant change are somewhat consistent with clients' own perceptions of required symptom change., (Copyright © 2022. Published by Elsevier Ltd.)
- Published
- 2022
- Full Text
- View/download PDF
26. Venous thromboembolism in patients hospitalised with COVID-19 in England.
- Author
-
Roberts LN, Navaratnam AV, Arya R, Briggs TWR, and Gray WK
- Subjects
- Adolescent, Adult, Hospitalization, Humans, Length of Stay, Male, Retrospective Studies, Risk Factors, COVID-19 complications, Venous Thromboembolism diagnosis, Venous Thromboembolism epidemiology, Venous Thromboembolism etiology
- Abstract
Background: The aim of this study was to detail the incidence of venous thromboembolism (VTE) in patients hospitalised with COVID-19 in England., Methods: This was an exploratory retrospective analysis of observational data from the Hospital Episode Statistics dataset for England. All patients aged ≥18 years in England with a diagnosis of COVID-19 who had a hospital stay that was completed between 1st March 2020 and 31st March 2021 were included. A recorded diagnosis of VTE during the index stay or during a subsequent admission in the six weeks following discharge was the primary outcome in the main analysis. In secondary analysis, VTE diagnosis was the primary exposure and in-hospital mortality the primary outcome., Results: Over the 13 months, 374,244 unique patients had a diagnosis of COVID-19 during a hospital stay, of whom 17,346 (4.6%) had a recorded diagnosis of VTE. VTE was more commonly recorded in patients aged 40-79 years, males and in patients of Black ethnicity, even after adjusting for covariates. Recorded VTE diagnosis was associated with longer hospital stay and higher adjusted in-hospital mortality (odds ratio 1.35 (95% confidence interval 1.29 to 1.41))., Conclusions: VTE was a common complication of hospitalisation with COVID-19 in England. VTE was associated with both increased length of stay and mortality rate., (Copyright © 2022 Elsevier Ltd. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
27. Evaluation of novel coagulation and platelet function assays in patients with chronic kidney disease.
- Author
-
Abdelmaguid A, Roberts LN, Tugores L, Joslin JR, Hunt BJ, Parmar K, Nebres D, Naga SS, Khalil ES, and Bramham K
- Subjects
- Blood Coagulation Tests, Cross-Sectional Studies, Female, Hemostasis, Humans, Intercellular Adhesion Molecule-1, Male, Thrombelastography, Thrombin, Kidney Failure, Chronic complications, Kidney Failure, Chronic diagnosis, Kidney Failure, Chronic therapy, Renal Insufficiency, Chronic complications, Renal Insufficiency, Chronic diagnosis, Thrombophilia diagnosis, Thrombophilia etiology
- Abstract
Background: Hemostasis evaluation in chronic kidney disease (CKD) is critical for optimal management of thrombotic and bleeding events. Standard coagulation screens are inadequate for predicting coagulopathy in CKD., Objective: To evaluate hemostasis parameters in patients with different stages of CKD using novel coagulation assays., Patients/methods: Cross-sectional study of 30 healthy controls (HC) and 120 CKD patients (10 Stage 2, 20 Stage 3, 20 Stage 4, 20 Stage 5 not requiring renal replacement therapy, 20 transplant, 10 newly started on hemodialysis [HD], 20 established on HD). Standard laboratory tests were performed in addition to rotational thromboelastometry (ROTEM), multiple electrode aggregometry (MEA), thrombin generation assays, D-dimer, and markers of thrombogenesis (thrombin-antithrombin [TAT]), fibrinolysis, and endothelial activation (intercellular adhesion molecule-1 [ICAM-1])., Results: D-dimer, TAT, and ICAM-1 concentrations were significantly higher in patients with CKD than HC (P < .01). ROTEM maximum clot firmness was significantly higher in patients than in HC (P < .01). In CKD Stage 5 patients (pre-HD and started HD) adenosine diphosphate and thrombin receptor activating peptide MEA tests were significantly lower than HC indicating platelet aggregation defect (P < .05). Multivariate analysis confirmed the direct effect of estimated glomerular filtration rate (eGFR) in the variance of ROTEM and MEA tests. Endogenous thrombin potential and peak thrombin were not statistically different between groups, but Stage 5 CKD patients had prolonged lag time (7.91 vs. 6.33, P < .001) and time to thrombin peak (10.8 vs. 9.5, P < .05) compared to HC., Conclusions: Patients with CKD exhibit features of concomitant hypercoagulability measured by ROTEM and platelet dysfunction measured with MEA. eGFR was an independent determinant of platelet dysfunction and hypercoagulability., (© 2022 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis.)
- Published
- 2022
- Full Text
- View/download PDF
28. Rivaroxaban for the treatment of superficial vein thrombosis, experience at King's College Hospital.
- Author
-
Clapham RE, Speed V, Czuprynska J, Gazes A, Guppy S, Patel RK, Rea C, Vadher B, Arya R, and Roberts LN
- Subjects
- Disease Management, Factor Xa Inhibitors administration & dosage, Factor Xa Inhibitors adverse effects, Humans, Rivaroxaban administration & dosage, Rivaroxaban adverse effects, Treatment Outcome, Venous Thrombosis diagnosis, Venous Thrombosis etiology, Factor Xa Inhibitors therapeutic use, Rivaroxaban therapeutic use, Venous Thrombosis drug therapy
- Published
- 2022
- Full Text
- View/download PDF
29. Periprocedural management of abnormal coagulation parameters and thrombocytopenia in patients with cirrhosis: Guidance from the SSC of the ISTH.
- Author
-
Roberts LN, Lisman T, Stanworth S, Hernandez-Gea V, Magnusson M, Tripodi A, and Thachil J
- Subjects
- Blood Coagulation, Hemostasis, Humans, Liver Cirrhosis complications, Liver Cirrhosis diagnosis, Blood Coagulation Disorders etiology, Thrombocytopenia complications, Thrombocytopenia diagnosis, Thrombocytopenia therapy
- Abstract
Prolonged prothrombin time and thrombocytopenia are common in patients with cirrhosis. These parameters do not reflect the overall hemostatic rebalance or bleeding risk in the periprocedural setting; however, attempts to correct these parameters remain frequent. We review the literature on periprocedural bleeding risk, bleeding risk factors, and the risk and benefits of hemostatic interventions in patients with cirrhosis. We provide guidance recommendations on evaluating bleeding risk in this patient group and management of hemostatic abnormalities in the periprocedural setting., (© 2021 International Society on Thrombosis and Haemostasis.)
- Published
- 2022
- Full Text
- View/download PDF
30. Clinical outcomes and the impact of prior oral anticoagulant use in patients with coronavirus disease 2019 admitted to hospitals in the UK - a multicentre observational study.
- Author
-
Arachchillage DJ, Rajakaruna I, Odho Z, Crossette-Thambiah C, Nicolson PLR, Roberts LN, Allan C, Lewis S, Riat R, Mounter P, Lynch C, Langridge A, Oakes R, Aung N, Drebes A, Dutt T, Raheja P, Delaney A, Essex S, Lowe G, Sutton D, Lentaigne C, Sayar Z, Kilner M, Everington T, Shapiro S, Alikhan R, Szydlo R, Makris M, and Laffan M
- Subjects
- Administration, Oral, Adult, Aged, Aged, 80 and over, Anticoagulants adverse effects, COVID-19 diagnosis, COVID-19 epidemiology, COVID-19 therapy, Female, Hemorrhage chemically induced, Hospitalization, Humans, Intensive Care Units, Male, Middle Aged, SARS-CoV-2 isolation & purification, Severity of Illness Index, Thrombosis epidemiology, United Kingdom epidemiology, Anticoagulants therapeutic use, COVID-19 complications, Thrombosis complications, Thrombosis drug therapy
- Abstract
Coagulation dysfunction and thrombosis are major complications in patients with coronavirus disease 2019 (COVID-19). Patients on oral anticoagulants (OAC) prior to diagnosis of COVID-19 may therefore have better outcomes. In this multicentre observational study of 5 883 patients (≥18 years) admitted to 26 UK hospitals between 1 April 2020 and 31 July 2020, overall mortality was 29·2%. Incidences of thrombosis, major bleeding (MB) and multiorgan failure (MOF) were 5·4%, 1·7% and 3·3% respectively. The presence of thrombosis, MB, or MOF was associated with a 1·8, 4·5 or 5·9-fold increased risk of dying, respectively. Of the 5 883 patients studied, 83·6% (n = 4 920) were not on OAC and 16·4% (n = 963) were taking OAC at the time of admission. There was no difference in mortality between patients on OAC vs no OAC prior to admission when compared in an adjusted multivariate analysis [hazard ratio (HR) 1·05, 95% confidence interval (CI) 0·93-1·19; P = 0·15] or in an adjusted propensity score analysis (HR 0·92 95% CI 0·58-1·450; P = 0·18). In multivariate and adjusted propensity score analyses, the only significant association of no anticoagulation prior to diagnosis of COVID-19 was admission to the Intensive-Care Unit (ICU) (HR 1·98, 95% CI 1·37-2·85). Thrombosis, MB, and MOF were associated with higher mortality. Our results indicate that patients may have benefit from prior OAC use, especially reduced admission to ICU, without any increase in bleeding., (© 2021 British Society for Haematology and John Wiley & Sons Ltd.)
- Published
- 2022
- Full Text
- View/download PDF
31. Rebalanced hemostasis in liver disease: a misunderstood coagulopathy.
- Author
-
Roberts LN
- Subjects
- Blood Coagulation, Blood Coagulation Disorders blood, Blood Coagulation Disorders physiopathology, Chronic Disease, Female, Hemorrhage blood, Hemorrhage physiopathology, Humans, Liver Diseases blood, Liver Diseases physiopathology, Middle Aged, Thrombosis blood, Thrombosis etiology, Thrombosis physiopathology, Blood Coagulation Disorders complications, Hemorrhage complications, Hemostasis, Liver Diseases complications
- Abstract
The combination of frequently abnormal hemostatic markers and catastrophic bleeding as seen with variceal hemorrhage has contributed to the longstanding misperception that chronic liver disease (CLD) constitutes a bleeding diathesis. Laboratory studies of hemostasis in liver disease consistently challenge this with global coagulation assays incorporating activation of the protein C pathway demonstrating rebalanced hemostasis. It is now recognized that bleeding in CLD is predominantly secondary to portal hypertension (rather than a coagulopathy) and additionally that these patients are at increased risk of venous thrombosis, particularly in the portal venous system. This narrative review describes the current understanding of hemostasis in liver disease, as well as the periprocedural management of hemostasis and anticoagulation for management of venous thromboembolism in patients with CLD., (Copyright © 2021 by The American Society of Hematology.)
- Published
- 2021
- Full Text
- View/download PDF
32. Long-term adherence to direct acting oral anticoagulants and the influence of health beliefs after switching from vitamin-K antagonists: Findings from the Switching Study.
- Author
-
Bartoli-Abdou JK, Patel JP, Vadher B, Brown A, Roberts LN, Patel RK, Arya R, and Auyeung V
- Subjects
- Anticoagulants therapeutic use, Fibrinolytic Agents, Humans, Vitamins, Atrial Fibrillation drug therapy, Factor Xa Inhibitors
- Abstract
Aims: Switching non-adherent patients prescribed anticoagulant treatment to a regime with less monitoring could lead to significant non-adherence. Health beliefs are known to influence medication adherence; however, the extent of this influence is unknown in patients switched from vitamin-K antagonists (VKAs) to direct oral anticoagulants (DOACs). This study aimed to determine adherence to long-term therapy in patients switched from VKAs to DOAC due to low time in therapeutic range (TTR) and if adherence is associated with health beliefs., Methods: The Switching Study is a longitudinal observational cohort study following patients for at least 1-year. 254 patients anticoagulated with VKAs for stroke prevention in atrial fibrillation (AF) or secondary prevention of venous thromboembolism (VTE) and TTR < 50% were recruited from anticoagulation clinics at King's College Hospital, London, UK. All participants were switched to DOAC and had health beliefs measured at baseline with VKA, 1-month and 12-months after switching., Results: Of the 220 patients who completed 12-month follow-up 39% had sub-optimal adherence measured by self-report. 23% were non-adherent according to prescriptions issued. Increasing concerns about anticoagulation over time relative to beliefs about necessity was associated with lower self-reported adherence (OR = 0.902 95%C.I: 0.836, 0.974; p = 0.008). At baseline, believing that medications in general were overused in healthcare was negatively associated with adherence to DOAC (β = -1.5, 95%C.I: -2.7, -0.3; p = 0.013)., Conclusions: Although many patients who switched were adherent to therapy long-term, between 23 and 39% of patients exhibited sub-optimal adherence: these patients can be identified through their modifiable health beliefs at the time of switching., (Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
33. Adherence to rivaroxaban for the treatment of venous thromboembolism-Results from the FIRST registry.
- Author
-
Speed V, Auyeung V, Patel JP, Cooper D, Miller S, Roberts LN, Patel RK, and Arya R
- Abstract
Background: Medication nonadherence can result in poor clinical outcomes and significant costs to health care providers. When treating venous thromboembolism (VTE), subtherapeutic anticoagulation may contribute to complications such as recurrent VTE or postthrombotic syndrome., Objectives: To describe the extent, reasons for, and predictors of nonadherence to rivaroxaban for the treatment of VTE in clinical practice in the United Kingdom reported by participants of the FIRST registry., Patients/methods: The FIRST registry was an observational, multicenter registry reporting on the use of rivaroxaban in routine clinical practice. FIRST registry participants completed an adherence screening questionnaire during their treatment and follow-up., Results: In total, 1028 participants completed 1660 questionnaires over 2 years. One hundred thirteen of 1028 (11%) reported nonadherence at 28 days (interquartile range, 21-45). Reasons given for nonadherence at 1 month were forgetfulness (8.6% vs 74.7%; P < .001), carelessness (2.7% vs 27.3%; P < .001) or a change in routine (7.4% vs 25.5%; P < .001) reported by adherent and nonadherent participants, respectively. Older age (10-year increments) was the strongest predictor of good adherence (adjusted odds ratio, 1.21; 95% confidence interval, 1.06-1.39; 1 = adherent)., Conclusions: Overall adherence to rivaroxaban was high, and most nonadherence was unintentional. Identification of those at risk of nonadherence may reduce the risk of VTE recurrence and long-term complications., (© 2021 The Authors. Research and Practice in Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis (ISTH).)
- Published
- 2021
- Full Text
- View/download PDF
34. Rivaroxaban in acute venous thromboembolism: UK prescribing experience.
- Author
-
Speed V, Patel JP, Cooper D, Miller S, Roberts LN, Patel RK, and Arya R
- Abstract
Background: Rivaroxaban was reported as effective as traditional therapies for the acute treatment of venous thromboembolism (VTE) with fewer major bleeding complications in the seminal Einstein program and is now a recommended option for the treatment of VTE around the world., Objective: To report the safety and efficacy of rivaroxaban in daily care for the management of acute VTE in the United Kingdom., Patients/method: The FIRST registry is a UK-only, multicenter, noninterventional, observational VTE study (NCT02248610). Consecutive patients diagnosed with acute VTE, managed with rivaroxaban, were recruited and followed for up to 5 years. The primary outcomes were treatment-emergent symptomatic objectively diagnosed recurrent VTE, major and clinically relevant nonmajor bleeding (CRNMB), and all-cause mortality., Results: A total of 1262 participants were recruited between 2014 and 2018. Participants were heterogeneous, with age range 18 to 95 years, weight 35 to 234 kg, and maximum body mass index 64.4 kg/m
2 . The median duration of treatment exposure was 135 days (interquartile range [IQR], 84-307) and overall follow-up 497 days (IQR, 175-991). There were seven episodes of symptomatic VTE recurrence, 0.6%, (0.74/100 patient-years; 95% confidence interval [CI], 0.19-1.28). There were 79 of 1239 (6.4%), 8.66 of 100 patient-years (95% CI, 6.90-10.73) first episodes of major or CRNMB, which were most frequently reported by women aged <50 years as abnormal vaginal bleeding., Conclusions: Rivaroxaban is an effective and safe single drug modality for the treatment of VTE in daily practice in the United Kingdom. Data to determine the optimal anticoagulation therapy for women of childbearing age are needed., (© 2021 The Authors. Research and Practice in Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis (ISTH).)- Published
- 2021
- Full Text
- View/download PDF
35. Are Individuals Always Aware of Their Trauma-Related Intrusive Thoughts? A Study of Meta-Awareness.
- Author
-
Nixon RDV, Roberts LN, Sun YJ, and Takarangi MKT
- Subjects
- Humans, Inhibition, Psychological, Cognition, Stress Disorders, Post-Traumatic
- Abstract
Individuals are not always aware of their mental content. We tested whether lack of awareness occurs in those who have experienced trauma, with and without posttraumatic stress disorder (PTSD). We also examined the role of proposed cognitive mechanisms (working memory and inhibition) in explaining unnoticed intrusions. Individuals with PTSD (n = 44), and varying levels of symptoms (high posttraumatic stress [PTS]: n = 24; low PTS: n = 37) reported on intrusive thoughts throughout a reading task. Intermittently, participants responded to probes about whether their thoughts were trauma related. Participants were "caught" engaging in unreported trauma-related thoughts (unnoticed intrusions) for between 24 and 27% of the probes in the PTSD and high PTS groups, compared with 15% of occasions in the low PTS group. For trauma-related intrusions only, participants lacked meta-awareness for almost 40% of probes in the PTSD group, which was significantly less than that observed in the other groups (∼60%). Contrary to predictions, working memory and response inhibition did not predict unnoticed intrusions. The results suggest that individuals who have experienced significant trauma can lack awareness about the frequency of their trauma-related thoughts. Further research is warranted to identify the mechanisms underpinning the occurrence of unnoticed intrusions., (Copyright © 2021. Published by Elsevier Ltd.)
- Published
- 2021
- Full Text
- View/download PDF
36. Treatment of bleeding in patients with liver disease.
- Author
-
Northup PG, Lisman T, and Roberts LN
- Subjects
- Gastrointestinal Hemorrhage diagnosis, Gastrointestinal Hemorrhage therapy, Hemostasis, Humans, Liver Cirrhosis complications, Liver Cirrhosis diagnosis, Liver Cirrhosis therapy, Blood Coagulation Disorders, Esophageal and Gastric Varices, Liver Diseases complications, Liver Diseases diagnosis, Liver Diseases therapy
- Abstract
Patients with cirrhosis frequently have complex alterations in their hemostatic system. Although routine diagnostic tests of hemostasis in cirrhosis (platelet count, prothrombin time, fibrinogen level) are suggestive of a bleeding tendency, it is now widely accepted that these tests do not reflect hemostatic competence in this population. Rather, patients with cirrhosis appear to have a rebalanced hemostatic system with hypercoagulable elements. Therefore, routine correction of hemostasis laboratory values, for example by fresh frozen plasma or platelet concentrates, with the aim to avoid spontaneous or procedure-related bleeding is not indicated as is outlined in recent clinical guidance documents. However, little guidance on how to manage patients with cirrhosis that are actively bleeding is available. Here we present three common bleeding scenarios, variceal bleeding, post-procedural bleeding and bleeding in a critically ill cirrhosis patient, with specific management suggestions. As patients with cirrhosis generally have adequate hemostatic competence and as bleeding complications may be unrelated to hemostatic failure, prohemostatic therapy is not the first line of management in bleeding patients with cirrhosis, even in the presence of markedly abnormal platelet counts and/or prothrombin times. We provide a rationale for the restrictive approach to prohemostatic therapy in bleeding patients with cirrhosis., (© 2021 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis.)
- Published
- 2021
- Full Text
- View/download PDF
37. Heparins have adequate ex vivo anticoagulant effects in hospitalized patients with cirrhosis.
- Author
-
van den Boom BP, von Meijenfeldt FA, Adelmeijer J, Roberts LN, Bernal W, and Lisman T
- Subjects
- Anticoagulants therapeutic use, Heparin, Low-Molecular-Weight therapeutic use, Humans, Liver Cirrhosis complications, Liver Cirrhosis diagnosis, Liver Cirrhosis drug therapy, Heparin therapeutic use, Venous Thromboembolism diagnosis, Venous Thromboembolism drug therapy
- Abstract
Background: Patients with cirrhosis are at risk of venous thromboembolism (VTE), but strategies for thromboprophylaxis have not been defined. Previous in vitro studies suggest an altered anticoagulant effect of heparins in patients with cirrhosis., Objectives: To assess the anticoagulant effects of prophylactic low-molecular-weight heparin (LMWH) or unfractionated heparin (UFH) doses in patients with cirrhosis in a real-life clinical setting., Methods: We studied patients with cirrhosis (n = 16) and acute-on-chronic liver failure (ACLF) (n = 14), and compared these with patients without underlying liver disease admitted to non-liver general medical wards (n = 18) and non-liver intensive care units (n = 14), respectively. Blood samples were taken before and 4 h after administration of the first dose of LMWH or UFH. We assessed hemostatic status using thrombin generation assays, thrombin-antithrombin complexes (TAT), and conventional coagulation assays, and included healthy controls (n = 20) to establish reference values. Anti-Xa activity was determined to estimate peak heparin levels., Results: Baseline thrombin generation was similar among all cohorts and healthy controls despite alterations in conventional coagulation assays. On heparin, both absolute and proportional changes of thrombin generation were comparable between all four cohorts (-62% to -85%). TAT levels decreased in all cohorts apart from the ACLF cohort, but did not correlate with the proportional change in thrombin generation. Anti-Xa activity correlated with the proportional change in thrombin generation in patients receiving LMWH, but not in patients receiving UFH., Conclusions: These data suggest that current prophylactic heparin doses have comparable anticoagulant effects in patients with cirrhosis compared with patients without underlying liver disease., (© 2021 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis.)
- Published
- 2021
- Full Text
- View/download PDF
38. Effect of type 1 diabetes and type 2 diabetes on the risk of venous thromboembolism.
- Author
-
Hinton W, Nemeth B, de Lusignan S, Field B, Feher MD, Munro N, Roberts LN, Arya R, and Whyte MB
- Subjects
- Adult, Aged, Aged, 80 and over, Cohort Studies, Diabetes Mellitus, Type 1 complications, Diabetes Mellitus, Type 1 therapy, Diabetes Mellitus, Type 2 complications, Diabetes Mellitus, Type 2 therapy, Diabetic Angiopathies epidemiology, Diabetic Angiopathies etiology, Female, Humans, Male, Middle Aged, Primary Health Care statistics & numerical data, Retrospective Studies, Risk Factors, United Kingdom epidemiology, Venous Thromboembolism etiology, Venous Thromboembolism therapy, Diabetes Mellitus, Type 1 epidemiology, Diabetes Mellitus, Type 2 epidemiology, Venous Thromboembolism epidemiology
- Abstract
Aims: Whether diabetes increases venous thromboembolism (VTE) is unclear. Any greater risk may relate to insulin resistance, but many studies did not differentiate between type 1 diabetes and type 2 diabetes for VTE risk., Methods: Retrospective cohort study of the Royal College of General Practitioners Research and Surveillance Centre, comprising over 530 primary care practices. We determined whether type 1 diabetes and/or type 2 diabetes are independent risk factors for VTE. The index date was 1 January 2009, individuals were followed to 31 December 2018, or censoring. Cox proportional hazard regression analysis was used to investigate the risk of VTE in people with type 1 diabetes and type 2 diabetes relative to no diabetes. The primary outcome was occurrence of VTE. The model was adjusted for potential confounders for VTE., Results: There were 7086 people with type 1 diabetes and 95,566 with type 2 diabetes, diagnosed before 1 January 2009. The non-diabetes group consisted of 1,407,699 people. In the unadjusted analysis, there was no increased risk of VTE with type 1 diabetes (HR 1.00, 95% CI 0.76-1.33) but there was for type 2 diabetes (HR 2.70, 95% CI 2.57-2.84). In the fully adjusted model, VTE risk was increased in type 1 diabetes (HR 1.46, 95% CI 1.11-1.92), but not with type 2 diabetes (HR 1.06, 95% CI 0.98-1.14)., Conclusions: Type 1 diabetes was associated with a greater risk for VTE while type 2 diabetes was not. Further work is needed to determine the reason(s) for this., (© 2020 The Authors. Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK.)
- Published
- 2021
- Full Text
- View/download PDF
39. The effect of microgravity on the human venous system and blood coagulation: a systematic review.
- Author
-
Kim DS, Vaquer S, Mazzolai L, Roberts LN, Pavela J, Watanabe M, Weerts G, and Green DA
- Subjects
- Blood Coagulation, Humans, Jugular Veins physiology, Space Flight, Thrombosis, Weightlessness adverse effects
- Abstract
New Findings: What is the central question of this study? Recently, an internal jugular venous thrombus was identified during spaceflight: does microgravity induce venous and/or coagulation pathophysiology, and thus an increased risk of venous thromboembolism (VTE)? What is the main finding and its importance? Whilst data are limited, this systematic review suggests that microgravity and its analogues may induce an enhanced coagulation state due to venous changes most prominent in the cephalad venous system, as a consequence of changes in venous flow, distension, pressures, endothelial damage and possibly hypercoagulability in microgravity and its analogues. However, whether such changes precipitate an increased VTE risk in spaceflight remains to be determined., Abstract: Recently, an internal jugular venous thrombus was identified during spaceflight, but whether microgravity induces venous and/or coagulation pathophysiology, and thus, an increased risk of venous thromboembolism (VTE) is unclear. Therefore, a systematic (Cochrane compliant) review was performed of venous system or coagulation parameters in actual spaceflight (microgravity) or ground-based analogues in PubMed, MEDLINE, Ovid EMBASE, Cochrane Library, European Space Agency, National Aeronautics and Space Administration, and Deutsches Zentrum für Luft-und Raumfahrt databases. Seven-hundred and eight articles were retrieved, of which 26 were included for evaluation with 21 evaluating venous, and five coagulation parameters. Nine articles contained spaceflight data, whereas the rest reported ground-based analogue data. There is substantial variability in study design, objectives and outcomes. Yet, data suggested cephalad venous system dilatation, increased venous pressures and decreased/reversed flow in microgravity. Increased fibrinogen levels, presence of thrombin generation markers and endothelial damage were also reported. Limited human venous and coagulation system data exist in spaceflight, or its analogues. Nevertheless, data suggest spaceflight may induce an enhanced coagulation state in the cephalad venous system, as a consequence of changes in venous flow, distension, pressures, endothelial damage and possibly hypercoagulability. Whether such changes precipitate an increased VTE risk in spaceflight remains to be determined., (© 2021 The Authors. Experimental Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society.)
- Published
- 2021
- Full Text
- View/download PDF
40. Three-month follow-up of pulmonary embolism in patients with COVID-19.
- Author
-
Whyte MB, Barker R, Kelly PA, Gonzalez E, Czuprynska J, Patel RK, Rea C, Perrin F, Waller M, Jolley C, Arya R, and Roberts LN
- Subjects
- Communication, Follow-Up Studies, Humans, Reference Standards, SARS-CoV-2, COVID-19, Pulmonary Embolism diagnosis, Venous Thromboembolism
- Published
- 2021
- Full Text
- View/download PDF
41. Prophylactic fresh frozen plasma and platelet transfusion have a prothrombotic effect in patients with liver disease.
- Author
-
von Meijenfeldt FA, van den Boom BP, Adelmeijer J, Roberts LN, Lisman T, and Bernal W
- Subjects
- Humans, Plasma, Platelet Transfusion adverse effects, Blood Coagulation Disorders, Liver Diseases diagnosis, Liver Diseases therapy, Thrombocytopenia diagnosis, Thrombocytopenia therapy
- Abstract
Background and Aims: Patients with liver disease acquire complex changes in their hemostatic system, resulting in prolongation of the international normalized ratio and thrombocytopenia. Abnormalities in these tests are commonly corrected with fresh frozen plasma (FFP) or platelet transfusions before invasive procedures. Whether these prophylactic transfusions are beneficial and truly indicated is increasingly debated. In this study, we studied ex vivo effects of FFP and platelet transfusions in patients with liver disease-associated hemostatic changes in a real-life clinical setting., Methods: We included 19 patients who were deemed to require prophylactic FFP transfusion by their treating physician and 13 that were prescribed platelet transfusion before a procedure. Hemostatic status was assessed in blood samples taken before and after transfusion and compared with healthy controls (n = 20)., Results: Ex vivo thrombin generation was preserved in patients with liver disease before FFP transfusion. Following FFP transfusion, both in and ex vivo thrombin generation significantly increased, as evidenced by a 92% and 38% increase in thrombin-antithrombin and prothrombin fragment 1 + 2 levels, respectively, and a 20% increase in endogenous thrombin potential. Platelet counts increased from 28 [21-41] × 10
9 /L before to 43 [39-64] × 109 /L after platelet transfusion (P < .01), and was accompanied by increases in in vivo markers of hemostatic activation., Conclusions: FFP and platelet transfusion resulted in increased thrombin generation and platelet counts in patients with liver disease, indicating a prothrombotic effect. However, whether all transfusions were truly indicated and had a clinically relevant effect is questionable., (© 2020 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis.)- Published
- 2021
- Full Text
- View/download PDF
42. Fixed dose rivaroxaban can be used in extremes of bodyweight: A population pharmacokinetic analysis - Reply to Jacobs & Ryan comment.
- Author
-
Speed V, Roberts LN, Arya R, and Patel JP
- Subjects
- Body Weight, Humans, Thiophenes, Anticoagulants, Rivaroxaban adverse effects
- Published
- 2021
- Full Text
- View/download PDF
43. More on enoxaparin thromboprophylaxis in pregnancy: A review of 10 years' experience from King's College Hospital.
- Author
-
Rajaratnam N, Patel JP, Roberts LN, Czuprynska J, Patel RK, and Arya R
- Subjects
- Anticoagulants adverse effects, Female, Hospitals, Humans, Pregnancy, Universities, Enoxaparin adverse effects, Venous Thromboembolism epidemiology, Venous Thromboembolism prevention & control
- Published
- 2021
- Full Text
- View/download PDF
44. UK real-world experience of prescribing rivaroxaban for acute venous thromboembolism in obesity: Results from the FIRST Registry.
- Author
-
Speed V, Patel JP, Roberts LN, Patel RK, and Arya R
- Subjects
- Anticoagulants therapeutic use, Factor Xa Inhibitors therapeutic use, Humans, Obesity complications, Obesity drug therapy, Registries, United Kingdom, Rivaroxaban therapeutic use, Venous Thromboembolism drug therapy
- Published
- 2021
- Full Text
- View/download PDF
45. Switching warfarin patients to a direct oral anticoagulant during the Coronavirus Disease-19 pandemic.
- Author
-
Patel R, Czuprynska J, Roberts LN, Vadher B, Rea C, Patel R, Gee E, Saul G, Coles E, Brown A, Byrne R, Speed V, Patel JP, and Arya R
- Subjects
- Administration, Oral, Anticoagulants adverse effects, COVID-19 blood, COVID-19 epidemiology, COVID-19 prevention & control, Counseling, Drug Monitoring, Hospitals, University organization & administration, Hospitals, University statistics & numerical data, Humans, Informed Consent, London epidemiology, Patient Acceptance of Health Care, Patient Education as Topic, Pyridines adverse effects, Quarantine, Rivaroxaban adverse effects, Telemedicine, Tertiary Care Centers organization & administration, Tertiary Care Centers statistics & numerical data, Thiazoles adverse effects, Thrombophilia etiology, Anticoagulants therapeutic use, COVID-19 complications, Drug Substitution methods, Pandemics, Pyridines therapeutic use, Rivaroxaban therapeutic use, SARS-CoV-2, Thiazoles therapeutic use, Thrombophilia drug therapy, Warfarin therapeutic use
- Published
- 2021
- Full Text
- View/download PDF
46. Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients With Liver Disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases.
- Author
-
Northup PG, Garcia-Pagan JC, Garcia-Tsao G, Intagliata NM, Superina RA, Roberts LN, Lisman T, and Valla DC
- Subjects
- Disease Management, Esophageal and Gastric Varices pathology, Esophageal and Gastric Varices surgery, Gastrointestinal Hemorrhage pathology, Gastrointestinal Hemorrhage prevention & control, Humans, Portal Vein pathology, Risk Assessment, Societies, Medical, United States, Esophageal and Gastric Varices etiology, Gastrointestinal Hemorrhage etiology, Liver Cirrhosis complications, Liver Cirrhosis pathology, Varicose Veins
- Published
- 2021
- Full Text
- View/download PDF
47. Pulmonary embolism in hospitalised patients with COVID-19.
- Author
-
Whyte MB, Kelly PA, Gonzalez E, Arya R, and Roberts LN
- Subjects
- Betacoronavirus isolation & purification, Blood Coagulation, COVID-19, Computed Tomography Angiography, Coronavirus Infections blood, Female, Fibrin Fibrinogen Degradation Products analysis, Hospitalization, Humans, Incidence, Male, Middle Aged, Pandemics, Pneumonia, Viral blood, Pulmonary Embolism blood, Pulmonary Embolism diagnostic imaging, Retrospective Studies, SARS-CoV-2, Coronavirus Infections complications, Pneumonia, Viral complications, Pulmonary Embolism etiology
- Abstract
Background: Coronavirus disease 2019 (COVID-19) is characterised by dyspnoea and abnormal coagulation parameters, including raised D-dimer. Data suggests a high incidence of pulmonary embolism (PE) in ventilated patients with COVID-19., Objectives: To determine the incidence of PE in hospitalised patients with COVID-19 and the diagnostic yield of Computer Tomography Pulmonary Angiography (CTPA) for PE. We also examined the utility of D-dimer and conventional pre-test probability for diagnosis of PE in COVID-19., Patients/methods: Retrospective review of single-centre data of all CTPA studies in patients with suspected or confirmed COVID-19 identified from Electronic Patient Records (EPR)., Results: There were 1477 patients admitted with COVID-19 and 214 CTPA scans performed, of which n = 180 (84%) were requested outside of critical care. The diagnostic yield for PE was 37%. The overall proportion of PE in patients with COVID-19 was 5.4%. The proportions with Wells score of ≥4 ('PE likely') was 33/134 (25%) without PE vs 20/80 (25%) with PE (P = 0.951). The median National Early Warning-2 (NEWS2) score (illness severity) was 5 (interquartile range [IQR] 3-9) in PE group vs 4 (IQR 2-7) in those without PE (P = 0.133). D-dimer was higher in PE (median 8000 ng/mL; IQR 4665-8000 ng/mL) than non-PE (2060 ng/mL, IQR 1210-4410 ng/mL, P < 0.001). In the 'low probability' group, D-dimer was higher (P < 0.001) in those with PE but had a limited role in excluding PE., Conclusions: Even outside of the critical care environment, PE in hospitalised patients with COVID-19 is common. Of note, approaching half of PE events were diagnosed on hospital admission. More data are needed to identify an optimal diagnostic pathway in patients with COVID-19. Randomised controlled trials of intensified thromboprophylaxis are urgently needed., (Copyright © 2020 Elsevier Ltd. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
48. Tranexamic acid in acute gastrointestinal bleeding - A cautionary tale.
- Author
-
Roberts LN
- Subjects
- Acute Disease, Gastrointestinal Hemorrhage chemically induced, Gastrointestinal Hemorrhage diagnosis, Humans, Antifibrinolytic Agents adverse effects, Tranexamic Acid adverse effects
- Published
- 2020
- Full Text
- View/download PDF
49. Postdischarge venous thromboembolism following hospital admission with COVID-19.
- Author
-
Roberts LN, Whyte MB, Georgiou L, Giron G, Czuprynska J, Rea C, Vadher B, Patel RK, Gee E, and Arya R
- Subjects
- COVID-19, Coronavirus Infections virology, Follow-Up Studies, Humans, Pandemics, Pneumonia, Viral virology, Prognosis, SARS-CoV-2, Venous Thromboembolism pathology, Betacoronavirus isolation & purification, Coronavirus Infections complications, Hospitalization statistics & numerical data, Patient Discharge statistics & numerical data, Pneumonia, Viral complications, Venous Thromboembolism etiology
- Abstract
The association of severe coronavirus disease 2019 (COVID-19) with an increased risk of venous thromboembolism (VTE) has resulted in specific guidelines for its prevention and management. The VTE risk appears highest in those with critical care admission. The need for postdischarge thromboprophylaxis remains controversial, which is reflected in conflicting expert guideline recommendations. Our local protocol provides thromboprophylaxis to COVID-19 patients during admission only. We report postdischarge VTE data from an ongoing quality improvement program incorporating root-cause analysis of hospital-associated VTE (HA-VTE). Following 1877 hospital discharges associated with COVID-19, 9 episodes of HA-VTE were diagnosed within 42 days, giving a postdischarge rate of 4.8 per 1000 discharges. Over 2019, following 18 159 discharges associated with a medical admission; there were 56 episodes of HA-VTE within 42 days (3.1 per 1000 discharges). The odds ratio for postdischarge HA-VTE associated with COVID-19 compared with 2019 was 1.6 (95% confidence interval, 0.77-3.1). COVID-19 hospitalization does not appear to increase the risk of postdischarge HA-VTE compared with hospitalization with other acute medical illness. Given that the risk-benefit ratio of postdischarge thromboprophylaxis remains uncertain, randomized controlled trials to evaluate the role of continuing thromboprophylaxis in COVID-19 patients following hospital discharge are required., (© 2020 by The American Society of Hematology.)
- Published
- 2020
- Full Text
- View/download PDF
50. Hypercoagulability and Anticoagulation in Patients With COVID-19 Requiring Renal Replacement Therapy.
- Author
-
Roberts LN, Bramham K, Sharpe CC, and Arya R
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.